Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2017

View Archived Issues

FDA grants orphan drug status to ADC Therapeutics' ADCT-402

Dragonfly Therapeutics enters strategic collaboration with Celgene

Tarix Orphan's TXA-127 granted orphan drug status in E.U. for epidermolysis bullosa

Coherus BioSciences receives complete response letter from FDA for CHS-1701

Spero Therapeutics gives update on development of antibacterial agents

Gilead Sciences submits NDA in U.S. for bictegravir/emtricitabine/tenofovir alafenamide

FDA grants rare pediatric disease designation to Fibrocell Science's FCX-013

SLC6A6 gene variant linked to vision loss is possibly amenable to nutritional therapy

Numerate to identify clinical candidates for Takeda using AI-driven platform

Update on Pieris Pharmaceuticals' collaboration agreement with AstraZeneca

Seres initiates phase III study of SER-109 in recurrent C. difficile infection

New clinical outcomes trial of Jardiance planned in chronic kidney disease

Sunshine Lake Pharma discloses orexin OX1 and OX2 receptor antagonists

Phase II DART study of dalantercept plus axitinib in RCC misses primary endpoint

Medshine Discovery patents IL-6 release inhibitors

Roche discovers cathepsin S inhibitors

Alkermes begins phase IIIb study of ALKS-5461 for adjunctive treatment of major depressive disorder

FDA accepts Bioverativ's IND for BIVV-001 for hemophilia A

Genentech and Roche identify JAK inhibitors

Blueprint Medicines discloses neurotrophic tyrosine kinase receptors inhibitors

Aimmune updates progress of phase III PALISADE trial of AR-101 in peanut allergy

Rotary and Bill & Melinda Gates Foundation announce commitment to eradicate polio

Final overall survival data reported for phase III trial of cediranib in ovarian cancer

Final data for talazoparib in BRCA-mutated breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...